BNTX Form 6-K: Q2 2025 Results & Development Update Filed

Rhea-AI Filing Summary

Filing: On August 4, 2025, BioNTech SE filed a Form 6-K reporting a development update and its financial results for the three and six months ended June 30, 2025.

Exhibit: The filing states that the interim condensed consolidated financial statements and the operating and financial review and prospects for the three and six months ended June 30, 2025 are attached as Exhibit 99.1 and are deemed filed under Section 18 of the Exchange Act.

Signatures: The report is signed by Ramón Zapata-Gomez, Chief Financial Officer, and Dr. Sierk Poetting, Chief Operating Officer, dated August 4, 2025. The Form 6-K body contains no financial line-item figures; readers are referred to Exhibit 99.1 for detailed results.

Positive

• Interim financial statements and operating review filed as Exhibit 99.1
• Report signed by CFO and COO
• Filing dated and formally incorporated under Section 18 of the Exchange Act

Negative

• No financial line-item figures or metrics are provided in the Form 6-K body

Insights

Financial Analyst

TL;DR: Routine Form 6-K filing; interim financials and management review attached as Exhibit 99.1—no figures included in the 6-K body.

BioNTech's Form 6-K notifies investors that the company's interim condensed consolidated financial statements and operating and financial review for Q2 and the six months ended June 30, 2025 are filed as Exhibit 99.1. The filing itself is procedural and does not present standalone financial metrics in the body, so material analysis requires review of Exhibit 99.1. Signatures from the CFO and COO indicate standard executive attestation.

Corporate Governance Expert

TL;DR: Governance disclosure appears standard: timely submission and executive sign-off; substantive details are contained in the attached exhibit.

The Form 6-K documents a development update and incorporates the interim financial statements and management's review by reference via Exhibit 99.1. The report is duly signed by the Chief Financial Officer and Chief Operating Officer and dated August 4, 2025. From a governance perspective, the filing meets routine disclosure expectations; investors should examine Exhibit 99.1 for audited or interim figures and forward-looking commentary.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF AUGUST 2025

COMMISSION FILE NUMBER 001-39081

BioNTech SE
(Translation of registrant’s name into English)

An der Goldgrube 12

D-55131 Mainz

Germany

+49 6131-9084-0
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐

DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

On August 4, 2025, BioNTech SE (the “Company”) provided a development update and reported its financial results for the three and six months ended June 30, 2025. The interim condensed consolidated financial statements as well as the operating and financial review and prospects of the Company for the three and six months ended June 30, 2025 are attached hereto as Exhibit 99.1 and shall be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and incorporated by reference herein.

SIGNATURE

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioNTech SE

By:

/s/ Ramón Zapata-Gomez

By:

/s/ Dr. Sierk Poetting

Name: Ramón Zapata-Gomez

Name: Dr. Sierk Poetting

Title: Chief Financial Officer

Title: Chief Operating Officer

Date: August 4, 2025

EXHIBIT INDEX

Exhibit			Description of Exhibit
99.1			Quarterly Report for the Three and Six Months Ended June 30, 2025

FAQ

What did BioNTech (BNTX) file on August 4, 2025?

BioNTech filed a Form 6-K reporting a development update and its financial results for the three and six months ended June 30, 2025.

Where are the interim financial statements for Q2 2025 included?

The interim condensed consolidated financial statements and the operating and financial review and prospects are included as Exhibit 99.1, which is deemed filed.

Does the Form 6-K include detailed financial numbers?

No. The Form 6-K body contains no financial line-item figures; detailed results are in Exhibit 99.1.

Who signed the Form 6-K for BioNTech?

The report is signed by Ramón Zapata-Gomez, Chief Financial Officer, and Dr. Sierk Poetting, Chief Operating Officer.

What date is shown on the filing?

The Form 6-K is dated August 4, 2025.